Skip to main navigation Skip to search Skip to main content

Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial

  • Wei Siang Chen
  • , Ning I. Yang
  • , Subodh Verma
  • , Min Hui Liu
  • , Kun Yi Chien
  • , Chia Wei Chen
  • , Adrian Quan
  • , Hwee Teoh
  • , Andrew T. Yan
  • , Kim A. Connelly
  • , Yu Hsiang Juan
  • , Ching Wen Chang
  • , C. David Mazer
  • , Chao Hung Wang*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • University of Toronto
  • St Michael's Hospital
  • Chang Gung University

Research output: Contribution to journal › Journal Article › peer-review

Abstract

Background – Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular and cardiorenal events in people across the spectrum of heart failure. Using proteomics analysis, this study investigated the potential benefits of SGLT2 inhibitors in primary prevention at a protein level in patients without diabetes or heart failure. Methods – This is a sub-study of the EMPA-HEART 2 CardioLink-7 trial, which randomized people without diabetes or clinically overt heart failure but with risk factors for adverse cardiac remodeling to empagliflozin (10 mg/day) or placebo for 6 months. Blood samples were collected during the randomization visit and at the 6-month follow-up visit for proteomics analysis. Our investigation involved two phases of approach: discovery and verification. Results – Samples from individuals assigned to empagliflozin (n = 21) and placebo (n = 22) (median baseline N-terminal pro-B-type natriuretic peptide levels: 33.9 and 78.4 pg/ml, respectively) were analyzed. In the discovery phase, 28 of 1622 proteins fulfilled our threshold for being differentially expressed at 6 months. Ten proteins were verified, including calmodulin-like protein 5, desmoplakin, hornerin, peroxiredoxin-2, macrophage colony-stimulating factor 1 receptor, endosialin, high-temperature requirement serine protease A1, immunoglobulin epsilon heavy chain, proteasome subunit beta type-5, and cerebellin-4. Compared to the placebo group, the expression of these proteins from baseline to 6 months was all significantly decreased in the empagliflozin group. Their functions involved ion channel signaling, fibrosis, oxidative stress, inflammation, apoptosis, immune response, proteolysis, and neuromodulation. Conclusion – Empagliflozin modified multiple biologically relevant pathways in the nondiabetes and non-heart failure setting. These findings should be considered hypothesis-generating and warrant validation in larger, adequately powered studies.

Original languageEnglish
Article numbere00358
Pages (from-to)e00358
Number of pages9
JournalCardiovascular Endocrinology and Metabolism
Volume15
Issue number2
DOIs
StatePublished - 06 2026

Bibliographical note

Publisher Copyright:
© 2026 The Author(s). Published by Wolters Kluwer Health, Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cardiovascular risk
  • proteomics
  • sodium–glucose cotransporter 2 inhibition

Fingerprint

Dive into the research topics of 'Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial'. Together they form a unique fingerprint.

Cite this